Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 39,507 |
|
|||||
| News | - | ||||||
| Day High | 1.23 | Low High |
|||||
| Day Low | 1.195 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AVROBIO Inc | AVRO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -3.23% | 1.20 | 17:59:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.23 | 1.195 | 1.23 | 1.20 | 1.24 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 332 | 39,507 | $ 1.21 | $ 47,962 | - | 0.57 - 1.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:09:45 | 30 | $ 1.195 | USD |
AVROBIO Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 54.73M | 44.86M | - | 0 | 12.4M | 0.28 | 4.41 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AVROBIO News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVRO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.24 | 1.29 | 1.195 | 1.25 | 136,754 | -0.04 | -3.23% |
| 1 Month | 1.25 | 1.31 | 1.15 | 1.25 | 166,079 | -0.05 | -4.00% |
| 3 Months | 1.35 | 1.39 | 1.01 | 1.25 | 308,507 | -0.15 | -11.11% |
| 6 Months | 1.54 | 1.61 | 1.01 | 1.33 | 281,766 | -0.34 | -22.08% |
| 1 Year | 0.902 | 1.70 | 0.57 | 1.28 | 974,646 | 0.298 | 33.04% |
| 3 Years | 10.32 | 12.005 | 0.56 | 2.08 | 688,558 | -9.12 | -88.37% |
| 5 Years | 20.18 | 29.32 | 0.56 | 5.52 | 543,149 | -18.98 | -94.05% |
AVROBIO Description
| Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease. |
